13th Annual Global Embolization Symposium & Technologies
Purpose : The aim of this study was to compare the treatment response, survival, liver function and adverse event incidence of drug-eluting bead transcatheter arterial chemoembolization (DEB-TACE) using CalliSpheres® microspheres (CSM) with conventional TACE (cTACE) in hepatocellular carcinoma (HCC) patients.
Material and Methods : Seventy-three HCC patients who received DEB-TACE (using CSM) or cTACE treatment were consecutively enrolled. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors at M1/M3/M6 post treatment, liver function indexes and adverse events were recorded. Progression free survival (PFS) and overall survival (OS) were also calculated.
Results : Objective response rate (ORR) of patients at M1, M3 and M6, disease control rate (DCR) of patients and ORR of nodules at M3 were increased in DEB-TACE group compared with cTACE group. In addition, DEB-TACE using CSM was an independent factor for predicting better ORR at M1. Patients in DEB-TACE group achieved longer PFS and similar OS compared to patients in cTACE group; Cox’s proportional hazards regression model analyses revealed that DEB-TACE using CSM was associated with better PFS while it did not affect OS. Meanwhile, most of the occurrences of abnormal liver function indexes were similar between two groups whereas DEB-TACE group had higher percentage of patients with total bile acid≥2 ULN compared to cTACE group at M1. Moreover, the adverse event incidences between two groups were similar.
Conclusions : DEB-TACE using CSM achieves better treatment response and PFS while equal safety compared to cTACE in HCC patients.